Ezalia Esa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ezalia Esa has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Yuslina Mat Yusoff
Hematology Unit, Cancer Research Centre (CaRC), Institute for Medical Research (IMR), National Institutes of Health (NIH)
3 shared publications Azly Sumanty Ab Ghani
Department of Pathology Hospital Sultanah Nur Zahirah, Ministry of Health Terengganu Malaysia
2 shared publications- Betty Lee-Sue Ho
Department of Pediatrics Hospital Umum Sarawak, Ministry of Health Sarawak Malaysia
2 shared publications Durar Aqilah Zamri
Genetics Department Hospital Tunku Azizah, Ministry of Health Kuala Lumpur Malaysia
2 shared publications- Faidatul Syazlin Abdul Hamid
Hematology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Seksyen U13 Setia Alam, Shah Alam, Selangor, 40170, Malaysia
2 shared publications - Muhamad Farid Zulkifle
Cancer Research Centre Institute for Medical Research, National Institutes of Health, Ministry of Health Selangor Malaysia
2 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (3)
Pilot of the International Hemoglobinopathy Research Network for a multiethnic genome-wide association study
- 16 April 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (3)
Open AccessPilot of the International Hemoglobinopathy Research Network for a multiethnic genome-wide association study
- Open Access
- 4 March 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (2) , 183-191
A Rare Case of De Novo α-Globin Cluster Duplication, ααα 102 (NC_000016.10: G.79903_181947dup) in a β-Thalassemia IVS 1-1 (G>T) ( HBB : C.92 + 1G>T) Carrier with Thalassemia Intermedia Phenotype
α-Globin triplication increases α/non-α-chain imbalance and may lead to a symptomatic β-thalassemia carrier. We describe a novel, de novo large segmental duplication, ααα102 in a patient who is a β-thalassemia IVS 1-1 (G > T) (HBB:c0.92 + 1G > T) carrier and presented with thalassemia intermedia. The duplication spans from intron II, position 203 of the N-methylpurine DNA glycosylase (MPG) gene, to the downstream region of the Hemoglobin Subunit Theta 1 (HBQ1) gene (GRCh38.p14) (HGVS NC_000016.10:g.79903_181947dup). The heterozygous β-thalassemia IVS 1-1 (G > T) was inherited from the father, while the mother was negative for thalassemia. α-MLPA analysis revealed multiple polymorphisms in the father; however, neither parent had the duplication. We concluded that the segmental duplication occurred de novo. In pre-marital screening programs, α-triplications and duplicated α-globin loci should be investigated when one partner has β-thalassemia or a β-thalassemia carrier.
- 4 March 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (2) , 183-191
Open AccessA Rare Case of De Novo α-Globin Cluster Duplication, ααα 102 (NC_000016.10: G.79903_181947dup) in a β-Thalassemia IVS 1-1 (G>T) ( HBB : C.92 + 1G>T) Carrier with Thalassemia Intermedia Phenotype
α-Globin triplication increases α/non-α-chain imbalance and may lead to a symptomatic β-thalassemia carrier. We describe a novel, de novo large segmental duplication, ααα102 in a patient who is a β-thalassemia IVS 1-1 (G > T) (HBB:c0.92 + 1G > T) carrier and presented with thalassemia intermedia. The duplication spans from intron II, position 203 of the N-methylpurine DNA glycosylase (MPG) gene, to the downstream region of the Hemoglobin Subunit Theta 1 (HBQ1) gene (GRCh38.p14) (HGVS NC_000016.10:g.79903_181947dup). The heterozygous β-thalassemia IVS 1-1 (G > T) was inherited from the father, while the mother was negative for thalassemia. α-MLPA analysis revealed multiple polymorphisms in the father; however, neither parent had the duplication. We concluded that the segmental duplication occurred de novo. In pre-marital screening programs, α-triplications and duplicated α-globin loci should be investigated when one partner has β-thalassemia or a β-thalassemia carrier.
- Open Access
- 2 March 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (3)
Single Nucleotide Polymorphism Microarray Analysis Unveils Copy‐Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B‐Cell Precursor Acute Lymphoblastic Leukemia
Introduction: B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP‐ALL in 55 Malaysian patients with BCP‐ALL. Methods: Single‐nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation‐dependent probe amplification were utilized to characterize and validate copy‐number abnormalities involving key oncogenes, respectively. Results: The SNP 6.0 microarray identified 191 copy‐number abnormalities in 55 patients, including common subtypes such as hyperdiploidy ( n = 14/191, 7.3%), hypodiploidy ( n = 2/191, 1.1%), and various copy‐number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin‐Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription‐polymerase chain reaction (RT‐PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy‐number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B , EBF1 , ERG , ETV6 , IKZF1 , JAK2 , and PAX5 . Conclusion: This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP‐ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
- 2 March 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (3)
Open AccessSingle Nucleotide Polymorphism Microarray Analysis Unveils Copy‐Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B‐Cell Precursor Acute Lymphoblastic Leukemia
Introduction: B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP‐ALL in 55 Malaysian patients with BCP‐ALL. Methods: Single‐nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation‐dependent probe amplification were utilized to characterize and validate copy‐number abnormalities involving key oncogenes, respectively. Results: The SNP 6.0 microarray identified 191 copy‐number abnormalities in 55 patients, including common subtypes such as hyperdiploidy ( n = 14/191, 7.3%), hypodiploidy ( n = 2/191, 1.1%), and various copy‐number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin‐Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription‐polymerase chain reaction (RT‐PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy‐number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B , EBF1 , ERG , ETV6 , IKZF1 , JAK2 , and PAX5 . Conclusion: This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP‐ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
- Open Access
- 1 March 2026
- Vol. 14 (3) , e70182
Single Nucleotide Polymorphism Microarray Analysis Unveils Copy-Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP-ALL in 55 Malaysian patients with BCP-ALL. Single-nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation-dependent probe amplification were utilized to characterize and validate copy-number abnormalities involving key oncogenes, respectively. The SNP 6.0 microarray identified 191 copy-number abnormalities in 55 patients, including common subtypes such as hyperdiploidy (n = 14/191, 7.3%), hypodiploidy (n = 2/191, 1.1%), and various copy-number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin-Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription-polymerase chain reaction (RT-PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy-number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B, EBF1, ERG, ETV6, IKZF1, JAK2, and PAX5. This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP-ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
- 1 March 2026
- Vol. 14 (3) , e70182
Open AccessSingle Nucleotide Polymorphism Microarray Analysis Unveils Copy-Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP-ALL in 55 Malaysian patients with BCP-ALL. Single-nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation-dependent probe amplification were utilized to characterize and validate copy-number abnormalities involving key oncogenes, respectively. The SNP 6.0 microarray identified 191 copy-number abnormalities in 55 patients, including common subtypes such as hyperdiploidy (n = 14/191, 7.3%), hypodiploidy (n = 2/191, 1.1%), and various copy-number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin-Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription-polymerase chain reaction (RT-PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy-number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B, EBF1, ERG, ETV6, IKZF1, JAK2, and PAX5. This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP-ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
- Open Access
- 26 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (39) , e44817
Novel HBB:c.375_376delAC mutation in a Malay patient with HbE beta-thalassemia intermedia: A case report
Rationale: Hemoglobin E beta-thalassemia (HbE-BT) is a prevalent and genetically diverse inherited hemoglobin disorder in Malaysia. While most cases are attributed to known genetic variants, discovering novel mutations is essential for understanding their wide-ranging clinical presentations and underlying genetic heterogeneity. Patient concerns: We present the case of a Malay male patient with an intermediate phenotype of HbE-BT whose clinical course was marked by a progression to a transfusion-dependent status, a change triggered by an acute febrile illness. The case highlights the complex challenges of long-term management, including a high risk of iron overload and the significant morbidity and mortality associated with postsplenectomy infections. Diagnoses: The patient was referred for a comprehensive DNA analysis of thalassemia syndromes. Full blood count showed hypochromic microcytic anemia (hemoglobin 7.90 g/dL, mean corpuscular volume 66.10 fL). Hemoglobin analysis via capillary electrophoresis revealed a characteristic pattern of HbA (49.1%), HbE (20.6%), and HbF (27.0%). Sanger sequencing subsequently confirmed a compound heterozygous state of HBB:c.79G>A (HbE) and a novel frameshift mutation at codon 124 of the beta-globin gene (HBB:c.375_376delAC). Predictive computational tools further supported the pathogenicity of this new variant, and its data have been submitted to the ITHANET database (IthaID: 4155). Interventions: Initially, the patient’s condition was managed with nutritional supplements and intermittent blood transfusions. Following an acute febrile episode at age 26, his clinical condition worsened, necessitating regular monthly blood transfusions to manage severe anemia. He also received subcutaneous chelation therapy to address severe hepatic iron overload. At age 36, he underwent a splenectomy to reduce his transfusion requirements. Outcomes: Despite these interventions, the patient passed away at the age of 37 from septic shock and multiorgan failure. This outcome occurred a year after his splenectomy and underscores the critical risk of overwhelming postsplenectomy infection, a significant complication in splenectomized thalassemia patients. Lessons: Identifying this novel compound heterozygosity contributes to our understanding of the genetic landscape of HbE-BT in Malaysia. This case reinforces the importance of comprehensive molecular analysis for accurate diagnosis, and it has important implications for improving long-term management and genetic counseling strategies for patients with thalassemia syndromes.
- 26 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (39) , e44817
Open AccessNovel HBB:c.375_376delAC mutation in a Malay patient with HbE beta-thalassemia intermedia: A case report
Rationale: Hemoglobin E beta-thalassemia (HbE-BT) is a prevalent and genetically diverse inherited hemoglobin disorder in Malaysia. While most cases are attributed to known genetic variants, discovering novel mutations is essential for understanding their wide-ranging clinical presentations and underlying genetic heterogeneity. Patient concerns: We present the case of a Malay male patient with an intermediate phenotype of HbE-BT whose clinical course was marked by a progression to a transfusion-dependent status, a change triggered by an acute febrile illness. The case highlights the complex challenges of long-term management, including a high risk of iron overload and the significant morbidity and mortality associated with postsplenectomy infections. Diagnoses: The patient was referred for a comprehensive DNA analysis of thalassemia syndromes. Full blood count showed hypochromic microcytic anemia (hemoglobin 7.90 g/dL, mean corpuscular volume 66.10 fL). Hemoglobin analysis via capillary electrophoresis revealed a characteristic pattern of HbA (49.1%), HbE (20.6%), and HbF (27.0%). Sanger sequencing subsequently confirmed a compound heterozygous state of HBB:c.79G>A (HbE) and a novel frameshift mutation at codon 124 of the beta-globin gene (HBB:c.375_376delAC). Predictive computational tools further supported the pathogenicity of this new variant, and its data have been submitted to the ITHANET database (IthaID: 4155). Interventions: Initially, the patient’s condition was managed with nutritional supplements and intermittent blood transfusions. Following an acute febrile episode at age 26, his clinical condition worsened, necessitating regular monthly blood transfusions to manage severe anemia. He also received subcutaneous chelation therapy to address severe hepatic iron overload. At age 36, he underwent a splenectomy to reduce his transfusion requirements. Outcomes: Despite these interventions, the patient passed away at the age of 37 from septic shock and multiorgan failure. This outcome occurred a year after his splenectomy and underscores the critical risk of overwhelming postsplenectomy infection, a significant complication in splenectomized thalassemia patients. Lessons: Identifying this novel compound heterozygosity contributes to our understanding of the genetic landscape of HbE-BT in Malaysia. This case reinforces the importance of comprehensive molecular analysis for accurate diagnosis, and it has important implications for improving long-term management and genetic counseling strategies for patients with thalassemia syndromes.
- Open Access
- 11 June 2022
- Published by Springer Nature in Genes & Genomics
- Vol. 44 (8) , 957-966
Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma
Background: Current advances in the molecular biology of multiple myeloma (MM) are not sufficient to fully delineate the genesis and development of this disease. Objective: This study aimed to identify molecular targets underlying MM pathogenesis. Methods: mRNA expression profiling for 29 samples (19 MM samples, 7 MM cell lines and 3 controls) were obtained using microarray. We evaluated the in vitro effects of RAD54L gene silencing on the proliferation, apoptosis and cell cycle distribution in KMS-28BM human MM cells using siRNA approach. Cell proliferation was determined by MTS assay while apoptosis and cell cycle distribution were analysed with flow cytometry. Gene and protein expression was evaluated using RT-qPCR and ELISA, respectively. Results: Microarray results revealed a total of 5124 differentially expressed genes (DEGs), in which 2696 and 2428 genes were up-regulated and down-regulated in MM compared to the normal controls, respectively (fold change ≥ 2.0; P < 0.05). Up-regulated genes (RAD54L, DIAPH3, SHCBP1, SKA3 and ANLN) and down-regulated genes (HKDC1, RASGRF2, CYSLTR2) have never been reported in association with MM. Up-regulation of RAD54L was further verified by RT-qPCR (P < 0.001). In vitro functional studies revealed that RAD54L gene silencing significantly induced growth inhibition, apoptosis (small changes) and cell cycle arrest in G0/G1 phase in KMS-28BM (P < 0.05). Silencing of RAD54L also decreased its protein level (P < 0.05). Conclusions: This study has identified possible molecular targets underlying the pathogenesis of MM. For the first time, we reveal RAD54L as a potential therapeutic target in MM, possibly functioning in the cell cycle and checkpoint control.
- 11 June 2022
- Published by Springer Nature in Genes & Genomics
- Vol. 44 (8) , 957-966
Open AccessGene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma
Background: Current advances in the molecular biology of multiple myeloma (MM) are not sufficient to fully delineate the genesis and development of this disease. Objective: This study aimed to identify molecular targets underlying MM pathogenesis. Methods: mRNA expression profiling for 29 samples (19 MM samples, 7 MM cell lines and 3 controls) were obtained using microarray. We evaluated the in vitro effects of RAD54L gene silencing on the proliferation, apoptosis and cell cycle distribution in KMS-28BM human MM cells using siRNA approach. Cell proliferation was determined by MTS assay while apoptosis and cell cycle distribution were analysed with flow cytometry. Gene and protein expression was evaluated using RT-qPCR and ELISA, respectively. Results: Microarray results revealed a total of 5124 differentially expressed genes (DEGs), in which 2696 and 2428 genes were up-regulated and down-regulated in MM compared to the normal controls, respectively (fold change ≥ 2.0; P < 0.05). Up-regulated genes (RAD54L, DIAPH3, SHCBP1, SKA3 and ANLN) and down-regulated genes (HKDC1, RASGRF2, CYSLTR2) have never been reported in association with MM. Up-regulation of RAD54L was further verified by RT-qPCR (P < 0.001). In vitro functional studies revealed that RAD54L gene silencing significantly induced growth inhibition, apoptosis (small changes) and cell cycle arrest in G0/G1 phase in KMS-28BM (P < 0.05). Silencing of RAD54L also decreased its protein level (P < 0.05). Conclusions: This study has identified possible molecular targets underlying the pathogenesis of MM. For the first time, we reveal RAD54L as a potential therapeutic target in MM, possibly functioning in the cell cycle and checkpoint control.